Budesonide delivered by Turbuhaler is effective in a dose-dependent fashion when used in the treatment of adult patients with chronic asthma William.

Slides:

Advertisements

Similar presentations

Inhaled corticosteroids decrease subepithelial collagen deposition by modulation of the balance between matrix metalloproteinase-9 and tissue inhibitor.

Advertisements

The Inhaled Steroid Treatment As Regular Therapy in Early Asthma (START) study 5- year follow-up: Effectiveness of early intervention with budesonide in.

Double-blind placebo-controlled study of the efficacy of oral terfenadine in the treatment of chronic fatigue syndrome Paul Steinberg, MDa, Bruce E.

Diane J. Pincus, MD, Stanley J. Szefler, MD, Lynn M

F.Estelle R. Simons, MDa, Bruce M. Prenner, MDb, Albert Finn, MDc

The XTEND-CIU study: Long-term use of omalizumab in chronic idiopathic urticaria Marcus Maurer, MD, Allen Kaplan, MD, Karin Rosén, MD, PhD, Michael Holden,

Fluticasone furoate nasal spray: A single treatment option for the symptoms of seasonal allergic rhinitis Harold B. Kaiser, MD, Robert M. Naclerio, MD,

Protective effect of inhaled budesonide against unlimited airway narrowing to methacholine in atopic patients with asthma Patrick Booms, MSca, David.

Enhanced synergy between fluticasone propionate and salmeterol inhaled from a single inhaler versus separate inhalers Harold S. Nelson, MDa, Kenneth.

Comparison of once-daily ebastine 20 mg, ebastine 10 mg, loratadine 10 mg, and placebo in the treatment of seasonal allergic rhinitis Paul H. Ratner,

The Effect of Tiotropium in Symptomatic Asthma Despite Low- to Medium-Dose Inhaled Corticosteroids: A Randomized Controlled Trial Pierluigi Paggiaro,

Dorothy M. Ryan, MD, Stephen J. Fowler, MD, Robert M. Niven, MD

Practice Notes from the AAAI

Badrul A. Chowdhury, MD, PhD

Hydroxychloroquine improves airflow and lowers circulating IgE levels in subjects with moderate symptomatic asthma B.Lauren Charous, MD, Elkan F. Halpern,

Comparison of the efficacy of budesonide and fluticasone propionate aqueous nasal spray for once daily treatment of perennial allergic rhinitis James.

Noninjection routes for immunotherapy

Lieuwe D. Bos, MSc, PhD, Peter J. Sterk, MD, PhD, Stephen J

A randomized multicenter study evaluating Xolair persistence of response after long- term therapy Dennis Ledford, MD, William Busse, MD, Benjamin Trzaskoma,

Elephantiasis nostras: A case report

Low-dose fluticasone propionate compared with montelukast for first-line treatment of persistent asthma: A randomized clinical trial William Busse, MDa,

The impact of allergic rhinitis on bronchial asthma

Inhaled fluticasone propionate delivered by means of two different multidose powder inhalers is effective and safe in a large pediatric population with.

Side effects of inhaled corticosteroids

Asthma symptom re-emergence after omalizumab withdrawal correlates well with increasing IgE and decreasing pharmacokinetic concentrations Raymond G.

Michael Mellon, MD Journal of Allergy and Clinical Immunology

Increased sensitivity to bradykinin among African Americans

Paul M. O’Byrne, MB, FRCPI, FRCP(C)a, Soren Pedersen, MD, PhDb

A methodological assessment of diurnal variability of peak flow as a basis for comparing different inhaled steroid formulations John H. Toogood, MD,

A review of the current guidelines for allergic rhinitis and asthma

Time for a paradigm shift in asthma treatment: From relieving bronchospasm to controlling systemic inflammation Leif Bjermer, MD Journal of Allergy.

Early decreases in blood eosinophil levels with reslizumab

News & Notes Journal of Allergy and Clinical Immunology

Inflammatory cells, cytokine and chemokine expression in asthma immunocytochemistry and in situ hybridization Qutayba Hamid, MD, PhD, Editor Journal.

Salmeterol and fluticasone propionate combined in a new powder inhalation device for the treatment of asthma: A randomized, double-blind, placebo-controlled.

Wine-induced asthma: A placebo-controlled assessment of its pathogenesis Hassan Vally, BSc (Hons), Amanda Carr, BAppSc, Jacque El-Saleh, RN, Philip Thompson,

Nicola A. Hanania, MB BS, MS, Bradley E. Chipps, MD, Noelle M

Efficacy of nebulized budesonide in treatment of severe infantile asthma: A double-blind study Jacques de Blic, MDa, Christophe Delacourt, MDa, Muriel.

Sharon Seth, MD, David A. Khan, MD

What is an “eosinophilic phenotype” of asthma?

Exercise-induced bronchoconstriction in children: Montelukast attenuates the immediate-phase and late-phase responses Raul E. Melo, MD, Dirceu Solé,

Clinical need for a nebulized corticosteroid

F.Estelle R. Simons, MDa, Bruce M. Prenner, MDb, Albert Finn, MDc

Fluticasone propionate powder administered through Diskhaler versus triamcinolone acetonide aerosol administered through metered-dose inhaler in patients.

Autophagy: Nobel Prize 2016 and allergy and asthma research

A comparison of multiple doses of fluticasone propionate and beclomethasone dipropionate in subjects with persistent asthma Gordon D. Raphael, MDa, Robert.

News & Notes Journal of Allergy and Clinical Immunology

Fluticasone propionate powder: Oral corticosteroid–sparing effect and improved lung function and quality of life in patients with severe chronic asthma

Low-dose inhaled fluticasone propionate versus oral zafirlukast in the treatment of persistent asthma Eugene R. Bleecker, MDa, Michael J. Welch, MDb,

A randomized, double-blind trial of the effect of treatment with montelukast on bronchial hyperresponsiveness and serum eosinophilic cationic protein.

Steroid-sparing effects of fluticasone propionate 100 μg and salmeterol 50 μg administered twice daily in a single product in patients previously controlled.

Protection by budesonide and fluticasone on allergen-induced airway responses after discontinuation of therapy Padmaja Subbarao, MD, MSc, Sandra C. Dorman,

Dose-ranging study of lebrikizumab in asthmatic patients not receiving inhaled steroids Michael Noonan, MD, Phillip Korenblat, MD, Sofia Mosesova, PhD,

Preparing patients and health professionals for the transition to chlorofluorocarbon-free inhalers: The British perspective Helen Donohoe, MSc (Econ)

Practice Notes from the AAAI

Washing the dog reduces dog allergen levels, but the dog needs to be washed twice a week Tessa Hodson, BSc, Adnan Custovic, MD, Angela Simpson, MD, Martin.

Mometasone furoate administered once daily is as effective as twice-daily administration for treatment of mild-to-moderate persistent asthma James P.

Efficacy and safety overview of a new inhaled corticosteroid, QVAR (hydrofluoroalkane- beclomethasone extrafine inhalation aerosol), in asthma Jennifer.

Eckard Hamelmann, MD, Eric D

Changes in sputum counts and airway hyperresponsiveness after budesonide: Monitoring anti-inflammatory response on the basis of surrogate markers of airway.

Pınar Uysal, MD, Esben Eller, MSc, PhD, Charlotte G

Further studies on the chronotherapy of asthma with inhaled steroids: The effect of dosage timing on drug efficacy Diane J. Pincus, MD, Teresa R. Humeston,

Diane J. Pincus, MD, Stanley J. Szefler, MD, Lynn M

Footnotes1 Journal of Allergy and Clinical Immunology

Larry C. Borish, MDa, Harold S

The preventive effect and duration of action of two doses of inhaled furosemide on exercise-induced asthma in children Elio Novembre, MD, Gianfranco.

Asthma symptoms and airway hyperresponsiveness are lower during treatment with nedocromil sodium than during treatment with regular inhaled albuterol

News & Notes Journal of Allergy and Clinical Immunology

Effect of codeine on objective measurement of cough in chronic obstructive pulmonary disease Jaclyn Smith, MD, PhD, Emily Owen, MPhil, John Earis, MD,

Clinical relevance of inhaled corticosteroids and HPA axis suppression

Presentation transcript:

Budesonide delivered by Turbuhaler is effective in a dose-dependent fashion when used in the treatment of adult patients with chronic asthma William W. Busse, MD, Paul Chervinsky, MD, John Condemi, MD, William R. Lumry, MD, Thomas L. Petty, MD, Stephen Rennard, MD, Robert G. Townley, MD Journal of Allergy and Clinical Immunology Volume 101, Issue 4, Pages 457-463 (April 1998) DOI: 10.1016/S0091-6749(98)70353-7 Copyright © 1998 Mosby, Inc. Terms and Conditions

FIG. 1 Discontinuations from study. Total percentage of patients (open bars) discontinuing from study and percentage of patients discontinued because of worsening asthma (closed bars) are shown for placebo- and budesonide-treated groups. Journal of Allergy and Clinical Immunology 1998 101, 457-463DOI: (10.1016/S0091-6749(98)70353-7) Copyright © 1998 Mosby, Inc. Terms and Conditions

FIG. 2 Mean change from baseline in morning PEF (L/min) for placebo and budesonide-treated groups. a, 2-week intervals and b, from baseline to week 12. Journal of Allergy and Clinical Immunology 1998 101, 457-463DOI: (10.1016/S0091-6749(98)70353-7) Copyright © 1998 Mosby, Inc. Terms and Conditions

FIG. 3 Mean change from baseline in morning FEV1 for placebo and budesonide-treated groups. a, 2-week intervals and b, from baseline to week 12. Journal of Allergy and Clinical Immunology 1998 101, 457-463DOI: (10.1016/S0091-6749(98)70353-7) Copyright © 1998 Mosby, Inc. Terms and Conditions